Demographic and medical characteristics
| . | 6 mo plus relapse-free survivors at pretransplant . | 5-y matched survivors* . | 5-y matched controls . | P (5-y survivors vs controls)† . |
|---|---|---|---|---|
| Total, no. | 112 | 77 | 77 | — |
| Mean age,y (SD), range‡ | 40.9 (9.3), 22-64 | 47.0 (8.9), 31-68 | 47.4 (9.8), 27-69 | NA |
| Sex | NA (matched) | |||
| Male | 54 (48) | 33 (43) | matched | — |
| Female | 58 (52) | 44 (57) | matched | — |
| Race or ethnicity | NA (matched) | |||
| White, non-Hispanic | 106 (95) | 74 (96) | matched | — |
| Nonwhite or Hispanic | 5 (4) | 3 (4) | matched | — |
| Unknown | 1 (1) | 0 (0) | matched | — |
| Education (highest degree) | NA (matched) | |||
| High school or less | 33 (29) | 20 (26) | 19 (25) | — |
| Trade or 2-y college | 21 (19) | 11 (14) | 14 (18) | — |
| College or postgraduate | 58 (52) | 46 (60) | 44 (57) | — |
| Income | .22 | |||
| Less than $45,000/y | 40 (36) | 23 (30) | 17 (22) | — |
| At least $45,000/y | 70 (62) | 51 (66) | 59 (77) | — |
| Unknown | 2 (2) | 3 (4) | 1 (1) | — |
| Marital status | .20 | |||
| Married or cohabiting | 84 (75) | 52 (68) | 58 (75) | — |
| Not married | 28 (25) | 25 (32) | 19 (25) | — |
| Self-reported menopausal status, women only | <.001 | |||
| Premenopausal | 21 (36) | 3 (7) | 21 (48) | — |
| Postmenopausal or perimenopausal | 32 (55) | 41 (93) | 22 (50) | — |
| Unknown | 5 (9) | 0 (0) | 1 (2) | — |
| Self-reported hormone therapy, women only | .003 | |||
| Take hormones | 18 (31) | 25 (57) | 11 (25) | — |
| Do not take hormones | 40 (69) | 18 (41) | 32 (73) | — |
| Unknown | 0 (0) | 1 (2) | 1 (2) | — |
| Diagnosis | ||||
| Chronic myeloid leukemia, chronic phase | 51 (46) | 34 (44) | NA | — |
| Chronic myeloid leukemia, accelerated phase or blast crisis | 9 (8) | 7 (9) | NA | — |
| Acute leukemia in remission | 16 (14) | 13 (17) | NA | — |
| Acute leukemia in relapse or de novo | 6 (5) | 5 (7) | NA | — |
| Myelodysplasias | 16 (14) | 9 (12) | NA | — |
| Lymphoma | 11 (10) | 8 (10) | NA | — |
| Multiple myeloma | 3 (3) | 1 (1) | NA | — |
| Stem-cell donor | ||||
| Allogeneic, related donor | 61 (54) | 47 (61) | NA | — |
| Allogeneic, unrelated donor | 51 (46) | 30 (39) | NA | — |
| Regimen included total body irradiation | ||||
| Total body irradiation | 65 (58) | 43 (56) | NA | — |
| No total body irradiation | 47 (42) | 34 (44) | NA | — |
| SF36 health-related quality of life: physical componenttscores | ||||
| Men, mean (SD) | 43.7 (10.8) | 46.5 (12.9) | 53.8 (6.2) | .007 |
| Women, mean (SD) | 49.6 (9.4) | 45.9 (12.0) | 51.7 (9.4) | .009 |
| SF36 health-related quality of life: mental componenttscores | ||||
| Men, mean (SD) | 49.2 (9.2) | 50.0 (10.4) | 51.7 (6.8) | .48 |
| Women, mean (SD) | 45.4 (12.1) | 46.8 (11.9) | 52.0 (10.4) | .04 |
| SFQ, sexually active in the past month | ||||
| Men | 36 (67) | 27 (82) | 33 (100) | .04 |
| Women | 30 (52) | 25 (57) | 35 (80) | .02 |
| SFQ, sexual function mean score | ||||
| Men, mean (SD) | 3.2 (0.9) | 3.2 (1.0) | 3.7 (0.6) | .01 |
| Women, mean (SD) | 2.2 (1.0) | 2.1 (1.1) | 2.6 (0.9) | .03 |
| . | 6 mo plus relapse-free survivors at pretransplant . | 5-y matched survivors* . | 5-y matched controls . | P (5-y survivors vs controls)† . |
|---|---|---|---|---|
| Total, no. | 112 | 77 | 77 | — |
| Mean age,y (SD), range‡ | 40.9 (9.3), 22-64 | 47.0 (8.9), 31-68 | 47.4 (9.8), 27-69 | NA |
| Sex | NA (matched) | |||
| Male | 54 (48) | 33 (43) | matched | — |
| Female | 58 (52) | 44 (57) | matched | — |
| Race or ethnicity | NA (matched) | |||
| White, non-Hispanic | 106 (95) | 74 (96) | matched | — |
| Nonwhite or Hispanic | 5 (4) | 3 (4) | matched | — |
| Unknown | 1 (1) | 0 (0) | matched | — |
| Education (highest degree) | NA (matched) | |||
| High school or less | 33 (29) | 20 (26) | 19 (25) | — |
| Trade or 2-y college | 21 (19) | 11 (14) | 14 (18) | — |
| College or postgraduate | 58 (52) | 46 (60) | 44 (57) | — |
| Income | .22 | |||
| Less than $45,000/y | 40 (36) | 23 (30) | 17 (22) | — |
| At least $45,000/y | 70 (62) | 51 (66) | 59 (77) | — |
| Unknown | 2 (2) | 3 (4) | 1 (1) | — |
| Marital status | .20 | |||
| Married or cohabiting | 84 (75) | 52 (68) | 58 (75) | — |
| Not married | 28 (25) | 25 (32) | 19 (25) | — |
| Self-reported menopausal status, women only | <.001 | |||
| Premenopausal | 21 (36) | 3 (7) | 21 (48) | — |
| Postmenopausal or perimenopausal | 32 (55) | 41 (93) | 22 (50) | — |
| Unknown | 5 (9) | 0 (0) | 1 (2) | — |
| Self-reported hormone therapy, women only | .003 | |||
| Take hormones | 18 (31) | 25 (57) | 11 (25) | — |
| Do not take hormones | 40 (69) | 18 (41) | 32 (73) | — |
| Unknown | 0 (0) | 1 (2) | 1 (2) | — |
| Diagnosis | ||||
| Chronic myeloid leukemia, chronic phase | 51 (46) | 34 (44) | NA | — |
| Chronic myeloid leukemia, accelerated phase or blast crisis | 9 (8) | 7 (9) | NA | — |
| Acute leukemia in remission | 16 (14) | 13 (17) | NA | — |
| Acute leukemia in relapse or de novo | 6 (5) | 5 (7) | NA | — |
| Myelodysplasias | 16 (14) | 9 (12) | NA | — |
| Lymphoma | 11 (10) | 8 (10) | NA | — |
| Multiple myeloma | 3 (3) | 1 (1) | NA | — |
| Stem-cell donor | ||||
| Allogeneic, related donor | 61 (54) | 47 (61) | NA | — |
| Allogeneic, unrelated donor | 51 (46) | 30 (39) | NA | — |
| Regimen included total body irradiation | ||||
| Total body irradiation | 65 (58) | 43 (56) | NA | — |
| No total body irradiation | 47 (42) | 34 (44) | NA | — |
| SF36 health-related quality of life: physical componenttscores | ||||
| Men, mean (SD) | 43.7 (10.8) | 46.5 (12.9) | 53.8 (6.2) | .007 |
| Women, mean (SD) | 49.6 (9.4) | 45.9 (12.0) | 51.7 (9.4) | .009 |
| SF36 health-related quality of life: mental componenttscores | ||||
| Men, mean (SD) | 49.2 (9.2) | 50.0 (10.4) | 51.7 (6.8) | .48 |
| Women, mean (SD) | 45.4 (12.1) | 46.8 (11.9) | 52.0 (10.4) | .04 |
| SFQ, sexually active in the past month | ||||
| Men | 36 (67) | 27 (82) | 33 (100) | .04 |
| Women | 30 (52) | 25 (57) | 35 (80) | .02 |
| SFQ, sexual function mean score | ||||
| Men, mean (SD) | 3.2 (0.9) | 3.2 (1.0) | 3.7 (0.6) | .01 |
| Women, mean (SD) | 2.2 (1.0) | 2.1 (1.1) | 2.6 (0.9) | .03 |
Data are numbers (%) except as noted.
— indicates no value; NA, not applicable; and SFQ, Sexual Function Questionnaire.
Includes 5-year survivors and their matched controls that both had sexual function responses (77 of 81).
Analyses were paired t tests for SF36 and SFQ mean, McNemar test for others.
Matched within 5 years of survivor's age.